Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$13.05 +0.94%

+$0.15 today

Market cap
$331.67M
Beta
0.48
P/E (TTM)
9.3
EPS (TTM)
$1.22
52W Low $11.98High $20.56

Volume 0.04M

Average 0.03M

CPH.TO Interest Expense

Cost of servicing the company's debt during the period.

Cipher Pharmaceuticals Inc.TSX: CPH.TO

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $50.16K fell 89.3% year over year, behind the -61.3% change in trailing-twelve-month interest expense. Sequentially, it fell 54.7% from the prior quarter.

Context

  • Interest expense amounted to 2.3% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.3% toward the trailing-twelve-month pace of -61.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$50.16K-54.7% QoQ
Last fiscal yearDec 2025
$1.19M— YoY
LTMMar 2026
$505.84K-61.3% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
1.19M USD
Year-over-year change
—
4-year CAGR
+89.5%

Interest Expense vs competitors

How CPH.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -61.3% is the 7th highest of 8, against a peer median of -30.8%.
  • Interest expense amounts to 1.0% of revenue for CPH.TO, versus a peer median of 3.0%.
CPH.TO Competitors
Interest Expense for CPH.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$41.67M CAD-44.1%-32.9%13.4%
TSND.TOTerrAscend Corp.LTM Mar 2026$37.61M USD+7.6%-0.9%14.4%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$11.31M CAD+34.6%+16.4%2.2%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$5.82M CAD-30.8%-64.2%1.8%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$5.68M CAD+52.7%+208.4%205.8%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$1.53M USD-57.9%+30.7%3.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$505.84K USD-61.3%—1.0%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$0 CAD-100.0%—0.0%
Peer median (excluding CPH.TO) —-30.8%+7.8%3.0%

Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.94M20.68M21.16M33.36M51.33M
Cost of Revenue3.68M3.99M4.07M9.26M17.56M
Gross Profit18.26M16.68M17.09M24.1M33.77M
Gross Margin83.2%80.7%80.8%72.2%65.8%
Research & Development88K98K139K021.37K
Selling, General & Admin5.11M4.4M5.43M12.24M16.3M
Operating Expenses6.45M5.63M5.56M16.26M16.97M
Depreciation & Amortization701K989K1.23M4.02M7.23M
EBITDA13.66M12.04M11.53M11.87M24.1M
EBITDA Margin62.2%58.2%54.5%35.6%46.9%
Operating Income11.82M12.04M11.53M7.85M16.8M
Operating Margin53.9%58.2%54.5%23.5%32.7%
Interest Income12K464K1.87M330K0
Interest Expense92K0001.19M
Other Income / Expenses(2M)(560K)1.15M(4.89M)661.38K
Income Before Tax11.06M11.48M12.68M2.96M17.46M
Pre-Tax Margin50.4%55.5%59.9%8.9%34.0%
Income Tax Expense3.3M(15.16M)(7.7M)(8.59M)(10.34M)
Net Income7.76M26.64M20.38M11.55M27.81M
Net Margin35.4%128.8%96.3%34.6%54.2%
EPS (Basic)0.291.060.800.471.09
EPS (Diluted)0.291.040.800.471.07
Weighted Avg Shares26.6M25.13M25.48M24.72M25.48M
Weighted Avg Shares (Diluted)26.83M25.59M25.42M24.57M25.99M

Cipher Pharmaceuticals Inc.

TSX:CPH.TO

Intrinsic Alpha fair value

Locked

Current Price

$13.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.